Here we describe a case of an HIV-infected young woman with extensive drug-resistant virus, who was successfully switched from a raltegravir-based regimen to a dolutegravir-based intensified antiretroviral regimen a few days before scheduled caesarean section because of the still detectable viral load. The trough concentrations of all antiretroviral drugs before and after delivery are also described. Our case underlines both the difficult management of young women, HIV-infected at young age with very limited treatment options and the great variability in the pregnancy-related physiological changes affecting the pharmacokinetics of antiretrovirals.
References
1.
GarciaP.M., KalishL.A., PittJ.Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.N Engl J Med1999; 341: 394–402.
2.
BestB.M., BurchettS., LiH.Pharmacokinetics of tenofovir during pregnancy and postpartum.HIV Med2015; 16: 502–511.
3.
ColbersA.P., HawkinsD.A., GingelmaierA.The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.AIDS2013; 27: 739–748.
4.
StekA., BestB.M., WangJ.Pharmacokinetics of once versus twice daily darunavir in pregnant HIV-infected women.J Acquir Immune Defic Syndr2015; 70: 33–41.
SchalkwijkS., Feiterna-SperlingC., WeizsäckerK.Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman.AIDS2016; 30: 1999–2001.
7.
MulliganN., BestB.M., CapparelliE.V., StekA., BarrE., SmithE.Dolutegravir pharmacokinetics in HIV-infected pregnant and postpartum women.Conference on Retroviruses and Opportunistic Infection, Boston, MA, USA, 22–25 February 2016. Abstract 438.
8.
HirtD., UrienS., EkouéviD.K.Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).Clin Pharmacol Ther2009; 85: 182–189.
9.
LambertJ., JacksonV., ElseL.Darunavir pharmacokinetics throughout pregnancy and postpartum.J Int AIDS Soc2014; 17: 19485.
10.
StaudF., CervenyL., CeckovaM.Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure.J Drug Target2012; 20: 736–763.
